Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents inflammatory injury induced by interferon-γ and histamine in NCTC 2544 keratinocytes

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 7, 2010, Pages 679-683

  Cardile, Venera ^a   Libra, Massimo ^a   Caggia, Silvia ^a   Frasca, Giuseppina ^a   Umezawa, Kazuo ^b   Stivala, Franca ^a   Mazzarino, Maria Clorinda ^a   Bevelacqua, Ylenia ^a   Coco, Marinella ^a   Malaponte, Grazia ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b KEIO UNIVERSITY   (Japan)

Author keywords

anti inflammatory activity; cytokines; dehydroxy methylepoxyquinomicin; ELISA; nuclear factor B; skin; western blot

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DEHYDROXYMETHYLEPOXYQUINOMICIN; GAMMA INTERFERON; HISTAMINE; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; ANTIINFLAMMATORY AGENT; BENZAMIDE DERIVATIVE; CCL2 PROTEIN, HUMAN; CYCLOHEXANONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; KERATINOCYTE; NONHUMAN; PROTEIN SECRETION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; CELL LINE; CHEMOKINE CCL2; CHEMOKINE CCL5; CYCLOHEXANONES; HISTAMINE; HUMANS; HYDROCORTISONE; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-8; KERATINOCYTES; NF-KAPPA B;

EID: 77953829765     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05375.x     Document Type: Article

References (28)

1. Matsumoto N, Ariga A, Nakamura H et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 2000 10: 865 869.
2. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 2002 277: 24.
3. Miyajima A, Kosaka T, Seta K, Asno T, Umezawa K, Hayakawa M. Novel nuclear factor κ B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J. Urol. 2003 169: 1559 1563.
4. Takatsuna H, Asagiri M, Kubota T et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1. J. Bone Miner. Res. 2005 20: 653 662.
5. Meng Z, Mitsutake N, Nakashima M et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 2008 149: 5357 5365.
6. Tatetsu H, Okuno Y, Nakamura M et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner. Mol. Cancer Ther. 2005 4: 1114 1120.
7. Matsumoto G, Namekawa J, Muta M et al. Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 2005 11: 1287 1293.
8. Kikuchi E, Horiguchi Y, Nakashima J et al. Suppression of hormone-refractory prostate cancer by a novel nuclear κB inhibitor in nude mice. Cancer Res. 2003 63: 107 110.
9. Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K. Antitumor effect of a novel nuclear factor-κB activation inhibitor in bladder cancer cells. Expert Rev. Anticancer Ther. 2003 3: 793 798.
10. Karin M, Lin A. NF-κB at crossroads of life and death. Nat. Immunol. 2002 3: 221 227.
11. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be. NF-κB is the answer: Role of Re1/NF-κB in the regulation of apoptosis. Oncogene 2003 22: 8961 8982.
12. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination. The control of NF-κB activity. Annu. Rev. Immunol. 2000 18: 621 663.
13. Huxford T, Malek S, Ghosh G. Structure and mechanism in NF-κB/IκB signaling. Cold Spring Harb. Symp. Quant. Biol. 1999 64: 533 540.
14. Baldwin AS Jr. The NF-κB and IκB proteins: New discoveries and insights. Annu. Rev. Immunol. 1996 14: 649 683.
15. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci. 2006 97: 990 995.
16. Albanesi C, Pastore S, Fanales-Belasio E, Girolomoni G. Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes. Clin. Exp. Allergy 1998 28: 101 109.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983 65: 55 63.
18. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and human inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J. Am. Acad. Dermatol. 1989 20: 617 629.
19. 2+ in cultured human keratinocytes. J. Dermatol. Sci. 1999 21: 137 142.
20. Kanda N, Watanabe S. Histamine enhances the production of nerve growth factor in human keratinocytes. J. Invest. Dermatol. 2003 121: 570 577.
21. Matsushima K, Oppenheim JJ. Interleukin 8 and MCAF. Novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine 1989 1: 2 13.
22. Schroder JM. Cytokine networks in the skin. J. Invest. Dermatol. 1995 105: 20S 4S.
23. Farrar MA, Schrieber RD. The molecular cell biology of interferon gamma and its receptor. Annu. Rev. Immunol. 1993 11: 571 611.
24. Shakov AN, Woerly G, Car BD, Ryffel B. Interferon-γ enhances tumor necrosis factor-α production by inhibiting early phase interleukin-10 transcription. Eur. Cytokine Netw. 1996 7: 741 750.
25. Ghosh S, May MJ, Kopp EB. NF-κ B and ReI proteins: Evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998 16: 225 260.
26. Chaicharoenpong C, Kato K, Umezawa K. Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-κB function. Bioorg. Med. Chem. 2002 10: 3933 3939.
27. Watanabe M, Nakashima M, Togano T et al. Identification of the RelA domain responsible for action of a new NF-κB inhibitor DHMEQ. Biochem. Biophys. Res. Commun. 2008 376: 310 314.
28. Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-κB inhibitors. Mol. Cells 2002 14: 163 167.